Research Scientist
Agriculture & Agri-Food Canada

Dr. Nancy Ames is a cereal research scientist with Agriculture and Agri-Food Canada located at the Richardson Centre for Functional Foods and Nutraceuticals in Winnipeg, Manitoba. Nancy Ames obtained her Ph.D. degree in Crop Science from the University of Guelph, MSc in Plant Science and BSc in Food Science both from the University of Manitoba. Her research work is primarily focused on nutrition and quality of oat, barley and wheat and the genetic, environmental and processing factors that affect overall value.

She works in conjunction with other researchers and the grain industry to develop wheat, oat and barley cultivars with added value processing and improved end product quality and to develop methods to predict quality characteristics of the raw and processed product. Dr. Ames has contributed significantly and creatively in the area of food product development and holds several food product patents. As well, Dr. Ames has authored and co-authored over 150 scientific papers, abstracts and book chapters. This includes two chapters from the recently published book “Oats Nutrition and Technology,” entitled (1) “Food Oat Quality throughout the Value Chain” and (2) “Health Claims for Oat Products: A Global Perspective”. Dr. Ames is also an adjunct Professor in the Department of Human Nutritional Sciences, Faculty of Human Ecology at the University of Manitoba. She is active on several committees for oats and barley including the American Association of Cereal Chemists International and Chair of the oat quality evaluation committee for the Prairie Grain Development Committee in western Canada. She is also a scientific advisor to the Healthy Grains Institute and the Quaker Centre of Excellence. Dr. Ames initiated efforts to substantiate and promote the health benefits of cereal grains. She acted as scientific lead in researching and preparing a petition for a therapeutic health claim: “barley beta-glucan soluble fibre and reduction of blood cholesterol, a risk factor for cardiovascular disease” which was approved by Health Canada in 2012.